Auto Accident
  Slip and Fall
  Medical Malpractice
  Construction Accidents
  Wrongful Death
  Workers Compensation
  Defective Drugs
  Product Liability
  Nursing Home Negligence
  Toxic Substances
  Lead Paint Poisoning

Public Health Alert Regarding Accutane
February 16, 2010

Health Canada has issued a public health alert regarding Accutane and its association with severe, and possibly fatal, skin reactions, including erythema multiforme [EM], Stevens-Johnson syndrome [SJS] and toxic epidermal necrolysis [TEN].

According to Health Canada, a review of the Roche global safety database found that as of November 22, 2009, 66 cases of severe skin reactions including EM, SJS and TEN, in adults and children have been reported worldwide in association with Accutane. Two of the cases were fatal. While there are confounding factors for the majority of the reports received, a causal association between Accutane and these severe skin reactions cannot be excluded, Health Canada said.

These severe skin reactions can start with mild non-specific symptoms such as fever, malaise, chills, aching muscles, headache, sore throat or stinging eyes. It can take up to 3 days for the skin lesions to develop.

People taking Accutane have been advised to stop taking the medication immediately and contact their doctor if they experience any of the following:

- rash, especially if associated with fever and/or malaise or conjunctivitis (red or inflamed eyes, like "pink eye")
- blisters on legs, arms or face and/or sores in mouth, throat, nose or eyes
- peeling skin
Accutane has been associated with a number of serious side effects, incluing severe birth defects, inflammatory bowel disease, problems of the liver, kidneys, central nervous system, and pancreas, as well as the cardiovascular, musculoskeletal and auto-immune systems. It has also been known to cause psychiatric problems, and has been linked to hundreds of cases of suicide in the U.S.

Last summer, Roche AG announced it would no longer sell Accutane in the U.S. and 11 other countries. The company cited declining sales as one of the major reasons behind the decision, as well as the high-cost of product liability suits and competition from generics. The last date for distribution of Accutane in the U.S. was June 25, 2009. At that time, Roche stopped direct distributions, but patients could still get Accutane from pharmacies that still had it in stock.



Website: http://www.yourlawyer.com/articles/read/17573

 
Bragoli & Associates, P.C.
300 Broadhollow Road, Suite 100 W
Melville, NY 11747
Tel. (631) 423-7755
Fax: (631) 423-5299
Toll Free: 1-888-529-9001
First Name:
*
Last Name:
*
Home Phone#:
Cell Phone#:
Bus. Phone#:
Best time to contact you:
E-mail:
*
Home Address:
Apt./Suite:
City:
State:
Zip Code:
Please describe your case:
Date of Incident/Accident:
Other Information:
 
Address. 300 Broadhollow Road, Suite 100 W, Melville, NY 11747 - Tel. (631) 423-7755 - Fax. (631) 423-5299
© Copyright 2008 Bragoli & Associates,P.C.